Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN; Department of Obstetrics and Gynecology, Faculty of Medicine, Assiut University, Assiut, Egypt.
Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN; Division of Minimally Invasive Gynecologic Surgery, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN.
Mayo Clin Proc. 2020 Apr;95(4):770-783. doi: 10.1016/j.mayocp.2019.10.009.
Fertility preservation (FP) is a vital issue for individuals in either reproductive or prepubescent stage of life when future fertility may be compromised. The objective of any FP intervention is to minimize or eliminate primary disease burden and to ensure maintaining or preserving reproductive health. Fertility potential can be affected by cancer therapy and numerous other factors, including advancing age, metabolic conditions, autoimmune diseases, specific surgical interventions, and sex affirmation procedures. A paradigm shift focusing on quality-of-life issues and long-term survivorship has emerged, especially because of advances in cancer diagnostics and treatment. Several FP techniques have been widely distributed, while others are still in the research stage. In addition, specific procedures and some potentially fertoprotective agents are being developed, aiming to minimize the hazards of gonadal damage caused by cancer therapy and decrease the need for more costly, invasive, and time-consuming FP methods. This review highlights the advances, indications, and options for FP, both experimental and well-established, in females of various age groups. An electronic search in PubMed, Embase, and Google Scholar databases was conducted, including retrospective studies, prospective clinical trials, meta-analyses, original reviews, and online abstracts published up to June 30, 2019. The search terms used included fertility preservation, oncofertility, embryo cryopreservation, oocyte cryopreservation, and ovarian tissue cryopreservation. The meeting proceedings of the American Society for Reproductive Medicine and the European Society of Human Reproduction and Embryology were also hand searched.
生育力保存(FP)是一个重要的问题,对于处于生殖或青春期的个体,未来的生育能力可能受到影响。任何 FP 干预的目的都是最大限度地减少或消除原发性疾病负担,并确保生殖健康得以维持或保存。生育能力可能会受到癌症治疗和许多其他因素的影响,包括年龄增长、代谢状况、自身免疫性疾病、特定的手术干预和性别确认程序。由于癌症诊断和治疗的进步,人们的关注点已经从疾病本身转移到生活质量和长期生存问题上。已经广泛应用了几种 FP 技术,而其他技术仍处于研究阶段。此外,正在开发特定的程序和一些潜在的生育保护剂,以尽量减少癌症治疗引起的性腺损伤的危害,并减少对更昂贵、侵入性和耗时的 FP 方法的需求。本文综述了女性在不同年龄段的 FP 技术的进展、适应证和选择,包括实验性和成熟的技术。在 PubMed、Embase 和 Google Scholar 数据库中进行了电子检索,包括回顾性研究、前瞻性临床试验、荟萃分析、原始综述和截至 2019 年 6 月 30 日发表的在线摘要。使用的检索词包括生育力保存、肿瘤生育力、胚胎冷冻保存、卵母细胞冷冻保存和卵巢组织冷冻保存。还对手动检索了美国生殖医学学会和欧洲人类生殖与胚胎学会的会议记录。